Efficacy vs tolerability in skin cancer: the Schlesinger perspective
AJMC's Todd Schlesinger, MD frames the central trade-off in modern skin cancer care — and why tolerability, not efficacy, increasingly determines who completes therapy.
Topic
Checkpoint Inhibitors
Topic
Checkpoint Inhibitors
First Patient Treated in Trial Targeting Immunotherapy Resistance
The Institute of Cancer Research has treated the first patient in a new clinical trial targeting immunotherapy resistance in lung…
Real-World Data Back Avelumab in Merkel Cell Carcinoma
Avelumab demonstrates effectiveness against Merkel cell carcinoma in a real-world population, Medscape reports, extending evidenc…
Northwestern: Radiotherapy Reshapes Immune Response in Skin Cancer
Northwestern University researchers report that radiotherapy reprograms the immune response in a rare cutaneous malignancy. The i…
Aulos Bioscience to Present Phase 1/2 Imneskibart Data at SITC 2026
Aulos Bioscience will present Phase 1/2 data for imneskibart combined with checkpoint inhibitors in NSCLC and melanoma at SITC 20…
Expert Consensus Maps Diagnosis, Treatment of Immunotherapy Skin Rashes
A new expert consensus lays out a structured framework for diagnosing and treating skin rashes in patients receiving cancer immun…
Personalized mRNA Vaccines Move Into the Melanoma Fight
Individually manufactured mRNA vaccines targeting tumor-specific neoantigens have entered clinical testing in melanoma, applying…
UCLA Study Identifies Factors Shaping Immunotherapy Response in Advanced Melanoma
UCLA Health researchers have identified factors that determine how advanced melanoma responds to immunotherapy, moving the field…